{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:13:25Z","timestamp":1790860405231,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Arba Minch University graduate program"},{"name":"Norwegian Programme for Capacity Development in Higher Education and Research","award":["ETH-13\/0025"],"award-info":[{"award-number":["ETH-13\/0025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-024-05087-7","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T08:32:40Z","timestamp":1726648360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic efficacy of artemether\u2013lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Arba Minch Zuria District, Gamo Zone, Southwest Ethiopia"],"prefix":"10.1186","volume":"23","author":[{"given":"Demeke","family":"Daka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Woldeyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemu","family":"Golassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gezahegn Solomon","family":"Alemayehu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerihun","family":"Zewde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girum","family":"Tamiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadesse","family":"Misganaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fekadu","family":"Massebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biniam","family":"Wondale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"5087_CR1","volume-title":"World malaria report 2022","author":"WHO","year":"2022","unstructured":"WHO. World malaria report 2022. Geneva: World Health Organization; 2022."},{"key":"5087_CR2","unstructured":"U.S. President\u2019s Malaria Initiative. Ethiopia Malaria Operational Plan FY. 2023"},{"key":"5087_CR3","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. Ethiopia malaria elimination strategic plan: 2021\u20132025. Ethiopia: Addis Ababa; 2020"},{"key":"5087_CR4","volume-title":"Global report on antimalarial drug efficacy and drug resistance: 2000\u20132010","author":"WHO","year":"2010","unstructured":"WHO. Global report on antimalarial drug efficacy and drug resistance: 2000\u20132010. Geneva: World Health Organization; 2010."},{"key":"5087_CR5","volume-title":"Guidelines for malaria \u2013 2021","author":"WHO","year":"2021","unstructured":"WHO. Guidelines for malaria \u2013 2021. Geneva: World Health Organization; 2021."},{"key":"5087_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"5087_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"5087_CR8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"5087_CR9","volume-title":"Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs","author":"LK Basco","year":"2007","unstructured":"Basco LK, Heseltine E, World Health Organization. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Geneva: World Health Organization; 2007."},{"key":"5087_CR10","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"5087_CR11","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. Diagnosis and treatment guidelines for health workers in Ethiopia. 2nd edn. Ethiopia: Addis Ababa; 2004."},{"key":"5087_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12936-020-03307-4","volume":"19","author":"A Abamecha","year":"2020","unstructured":"Abamecha A, Yilma D, Addisu W, Abid H, El IA, Noedl H, et al. Therapeutic efcacy of artemether\u2013lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District, Ethiopia. Malar J. 2020;19:240.","journal-title":"Malar J"},{"key":"5087_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12936-022-04436-8","volume":"22","author":"K Gubae","year":"2023","unstructured":"Gubae K, Mohammed H, Sime H, Hailgiorgis H, Mare AK, Gidey B, et al. Safety and therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at Shecha health centre, Arba Minch, Ethiopia. Malar J. 2023;22:9.","journal-title":"Malar J"},{"key":"5087_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12936-022-04182-x","volume":"21","author":"MM Plucinski","year":"2022","unstructured":"Plucinski MM, Ashley EA, Bassat Q, Venkatesan M, Rosenthal PJ, Halsey ES. STARTER checklist for antimalarial therapeutic efficacy reporting. Malar J. 2022;21:187.","journal-title":"Malar J"},{"key":"5087_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000070751","volume":"12","author":"J Iqbal","year":"2003","unstructured":"Iqbal J, Hira PR, Al-Ali F, Khalid N, Sher A. Modified Giemsa staining for rapid diagnosis of malaria infection. Med Princ Pract. 2003;12:156\u20139.","journal-title":"Med Princ Pract"},{"key":"5087_CR16","volume-title":"Malaria parasite counting","author":"WHO","year":"2016","unstructured":"WHO. Malaria parasite counting. Geneva: World Health Organization; 2016."},{"key":"5087_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1383-5769(97)00013-5","volume":"1","author":"M Kimura","year":"1997","unstructured":"Kimura M, Kaneko O, Liu Q, Zhou M, Kawamoto F, Wataya Y, et al. Identification of the four species of human malaria parasites by nested PCR that targets variant sequences in the small subunit rRNA gene. Parasitol Int. 1997;1:91\u20135.","journal-title":"Parasitol Int"},{"key":"5087_CR18","volume-title":"Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations","author":"WHO","year":"2008","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008."},{"key":"5087_CR19","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015."},{"key":"5087_CR20","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1038\/s41467-021-24814-1","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Wang C, Oberstaller J, Thomas P, Otto TD, Casandra D, et al. The apicoplast link to fever-survival and artemisinin-resistance in the malaria parasite. Nat Commun. 2021;12:4563.","journal-title":"Nat Commun"},{"key":"5087_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12936-022-04350-z","volume":"21","author":"A Assefa","year":"2022","unstructured":"Assefa A, Mohammed H, Anand A, Abera A, Sime H, Minta AA, et al. Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia. Malar J. 2022;21:359.","journal-title":"Malar J"},{"key":"5087_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154618","volume":"11","author":"D Nega","year":"2016","unstructured":"Nega D, Assefa A, Mohamed H, Solomon H, Woyessa A, Assefa Y, et al. Therapeutic efficacy of artemether-lumefantrine (Coartem\u00ae) in treating uncomplicated Plamodium falciparum malaria in Metehara, Eastern Ethiopia: regulatory clinical study. PLoS ONE. 2016;11: e0154618.","journal-title":"PLoS ONE"},{"key":"5087_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176004","volume":"12","author":"M Teklemariam","year":"2017","unstructured":"Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efcacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS ONE. 2017;12: e0176004.","journal-title":"PLoS ONE"},{"key":"5087_CR24","volume-title":"Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 7 (2016\u20132017)","author":"WHO","year":"2017","unstructured":"WHO. Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 7 (2016\u20132017). Geneva: World Health Organization; 2017."},{"key":"5087_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","volume":"37","author":"NJ White","year":"1999","unstructured":"White NJ, Van Vugt M, Ezzet FD. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999;37:105\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"5087_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12936-021-04021-5","volume":"20","author":"C Ebong","year":"2021","unstructured":"Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20:484.","journal-title":"Malar J"},{"key":"5087_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12936-015-0775-3","volume":"14","author":"G Getnet","year":"2015","unstructured":"Getnet G, Fola AA, Alemu A, Getie S, Fuehrer HP, Noedl H. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia. Malar J. 2015;14:258.","journal-title":"Malar J"},{"key":"5087_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41579-019-0306-2","volume":"18","author":"K Venugopal","year":"2020","unstructured":"Venugopal K, Hentzschel F, Valki\u016bnas G, Marti M. Plasmodium asexual growth and sexual development in the haematopoietic niche of the host. Nat Rev Microbiol. 2020;18:177\u201389.","journal-title":"Nat Rev Microbiol"},{"key":"5087_CR29","first-page":"45","volume":"3","author":"DL Gardiner","year":"2015","unstructured":"Gardiner DL, Trenholme KR. Plasmodium falciparum gametocytes: playing hide and seek. Ann Transl Med. 2015;3:45.","journal-title":"Ann Transl Med"},{"key":"5087_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/1475-2875-13-319","volume":"13","author":"S Karl","year":"2014","unstructured":"Karl S, Laman M, Koleala T, Ibam C, Kasian B, N\u2019Drewei N, et al. Comparison of three methods for detection of gametocytes in Melanesian children treated for uncomplicated malaria. Malar J. 2014;13:319.","journal-title":"Malar J"},{"key":"5087_CR31","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.4269\/ajtmh.20-0852","volume":"103","author":"MM Ippolito","year":"2020","unstructured":"Ippolito MM, Pringle JC, Siame M, Katowa B, Aydemir O, Oluoch PO, et al. Therapeutic efficacy of artemether\u2013lumefantrine for uncomplicated falciparum malaria in Northern Zambia. Am J Trop Med Hyg. 2020;103:2224\u201332.","journal-title":"Am J Trop Med Hyg"},{"key":"5087_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12936-019-3032-3","volume":"18","author":"P Omondi","year":"2019","unstructured":"Omondi P, Burugu M, Matoke-Muhia D, Too E, Nambati EA, Chege W, et al. Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether\u2013lumefantrine or dihydroartemisinin\u2013piperaquine treatment. Malar J. 2019;18:398.","journal-title":"Malar J"},{"key":"5087_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12936-019-2763-5","volume":"18","author":"S Lawpoolsri","year":"2019","unstructured":"Lawpoolsri S, Sattabongkot J, Sirichaisinthop J, Cui L, Kiattibutr K, Rachaphaew N, et al. Epidemiological profiles of recurrent malaria episodes in an endemic area along the Thailand-Myanmar border: a prospective cohort study. Malar J. 2019;18:124.","journal-title":"Malar J"},{"key":"5087_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1475-2875-11-176","volume":"11","author":"A F\u00e4rnert","year":"2012","unstructured":"F\u00e4rnert A, Ursing J, Tolfvenstam T, Rono J, Karlsson L, Sparrelid E, et al. Artemether\u2013lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania. Malar J. 2012;11:176.","journal-title":"Malar J"},{"key":"5087_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1586\/14787210.2016.1106938","volume":"14","author":"T Mita","year":"2016","unstructured":"Mita T, Tachibana SI, Hashimoto M, Hirai M. Plasmodium falciparum kelch 13: a potential molecular marker for tackling artemisinin-resistant malaria parasites. Expert Rev Anti Infect Ther. 2016;14:125\u201335.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5087_CR36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/1475-2875-10-352","volume":"10","author":"PN Newton","year":"2011","unstructured":"Newton PN, Green MD, Mildenhall DC, Plan\u00e7on A, Nettey H, Nyadong L, et al. Poor quality vital anti-malarials in Africa-an urgent neglected public health priority. Malar J. 2011;10:352.","journal-title":"Malar J"},{"key":"5087_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12916-018-1177-5","volume":"16","author":"D Das","year":"2018","unstructured":"Das D, Grais RF, Okiro EA, Stepniewska K, Mansoor R, Van Der Kam S, et al. Complex interactions between malaria and malnutrition: a systematic literature review. BMC Med. 2018;16:186.","journal-title":"BMC Med"},{"key":"5087_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17425255.2022.2049235","volume":"18","author":"L Pernaute-Lau","year":"2022","unstructured":"Pernaute-Lau L, Camara M, N\u00f3brega de Sousa T, Morris U, Ferreira MU, Gil JP. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria. Expert Opin Drug Metabol Toxicol. 2022;18:39\u201359.","journal-title":"Expert Opin Drug Metabol Toxicol"},{"key":"5087_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12936-019-2848-1","volume":"18","author":"B Abuaku","year":"2019","unstructured":"Abuaku B, Quashie ND, Quaye L, Matrevi SA, Quashie N, Gyasi A, et al. Therapeutic efficacy of artesunate-amodiaquine and artemether\u2013lumefantrine combinations for uncomplicated malaria in 10 sentinel sites across Ghana: 2015\u20132017. Malar J. 2019;18:206.","journal-title":"Malar J"},{"key":"5087_CR40","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820003167","volume":"149","author":"G Kishoyian","year":"2021","unstructured":"Kishoyian G, Njagi EN, Orinda GO, Kimani FT, Thiongo K, Matoke-Muhia D. Efficacy of artemisinin\u2013lumefantrine for treatment of uncomplicated malaria after more than a decade of its use in Kenya. Epidemiol Infect. 2021;149: e27.","journal-title":"Epidemiol Infect"},{"key":"5087_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.","journal-title":"Malar J"},{"key":"5087_CR42","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/TCRM.S113603","volume":"12","author":"F Wudneh","year":"2016","unstructured":"Wudneh F, Assefa A, Nega D, Mohammed H, Solomon H, Kebede T, et al. Open-label trial on efficacy of artemether\/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district, Northwestern Ethiopia. Ther Clin Risk Manag. 2016;12:1293\u2013300.","journal-title":"Ther Clin Risk Manag"},{"key":"5087_CR43","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41564-021-00962-4","volume":"10","author":"SM Feleke","year":"2021","unstructured":"Feleke SM, Reichert EN, Mohammed H, Brhane BG, Mekete K, Mamo H, et al. Plasmodium falciparum is evolving to escape malaria rapid diagnostic tests in Ethiopia. Nat Microbiol. 2021;10:1289\u201399.","journal-title":"Nat Microbiol"},{"key":"5087_CR44","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3201\/eid2702.191410","volume":"2","author":"C Prosser","year":"2021","unstructured":"Prosser C, Gresty K, Ellis J, Meyer W, Anderson K, Lee R, et al. Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions in strains from Nigeria, Sudan, and South Sudan. Emerg Infect Dis. 2021;2:471.","journal-title":"Emerg Infect Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05087-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-05087-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05087-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T07:07:10Z","timestamp":1726729630000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-05087-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5087"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-05087-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out following ethical approval obtained from the Research Ethics Review Board of Arba Minch University (Ref. N<u>o<\/u>: IRB\/1293\/2022). Written informed consent was obtained from each study participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have read the final manuscript and provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}